Blog: IMUNON, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01. Regulation FD Disclosure

On November 14, 2022, Imunon, Inc. (the “Company”) held a conference call to
discuss its financial results for the quarter and nine months ended September
30, 2022 and provide a business update. Attached as Exhibits 99.1 and 99.2 are
the conference call script and the Company’s November 2022 corporate

The information in this report, including the exhibits hereto, is being
furnished and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. Such information shall not be incorporated by reference into
any filing with the Securities and Exchange Commission made by Imunon, Inc.,
whether made before or after the date hereof, regardless of any general
incorporation language in such filing.

The exhibits contain forward-looking statements which involve certain risks and
uncertainties that could cause actual results to differ materially from those
expressed or implied by such statements. Please refer to the cautionary note
regarding forward looking statements in Imunon’s SEC filings.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

  No.     Description

 99.1       Script from third quarter earnings teleconference held November 14,
 99.2       Imunon, Inc. Corporate Presentation - November 2022
  104     Cover Page Interactive Data File (embedded within the Inline XBRL

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s